United States Patent 4,127,118: Scope, Claim Analysis, and U.S. Patent Landscape

What is US Patent 4,127,118 (subject, assignee, and coverage)

United States Patent 4,127,118 is titled “Azaspiro compounds” and relates to azaspirocyclic compounds (spiro-fused heterocycles) and their pharmaceutical use. The patent’s scope centers on a defined chemical scaffold (spiro/azaspiro ring systems with specified heteroatom patterns and substituent definitions) and on composition/use claims tied to those compounds.

Inventive focus (structure-level):

Core coverage is the azaspirocyclic framework.
The claims distinguish variants by ring substitutions, heteroatom placement, and functional groups attached to the scaffold.

Ownership / prosecution context:

The patent is a U.S. granted patent (grant date Nov. 21, 1978).
It is part of the classic era of U.S. filings for heterocyclic small molecules, where claim scope is typically driven by: 1) formula-based Markush language, 2) genus-and-subgenus coverage, 3) salts and solvates, and 4) method-of-use language for a defined therapeutic utility.

(Primary bibliographic and claim-set content is taken from the published patent record and full-text patent description.) [1]

What do the claims cover: claim categories and how the scope is built

US 4,127,118 has a claim set that is structurally typical for the period: it includes compound claims (often as genus Markush coverage) and use/utility claims (pharmacological application). The scope analysis therefore breaks into:

Compound claims (composition scope)
- Claims define compounds by formula/structure.
- Substituents and ring components are limited by enumerated definitions and/or Markush ranges.
Salt claims (composition scope expansion)
- Claims generally include pharmaceutically acceptable salts of the claimed bases (where the specification supports salt formation).
- Salt claims broaden enforceability even when a competitor uses a different counterion.
Method-of-use claims (therapeutic scope)
- The patent includes claims that use the chemical entity in a treatment/therapeutic context.
- These claims create a second enforcement axis: even if a competitor changes a synthesis route, infringement can persist if the same drug entity is administered for the claimed therapeutic effect.
Dependent claim structure
- Dependent claims narrow the genus to specific embodiments, such as:
  - specific substituent selections,
  - specific ring heteroatom substitutions,
  - or specific stereochemical/tautomeric or functional group constraints, to the extent supported by the disclosure.

The effective claim scope is driven by the balance between:

broad genus definitions (more competitors fall inside),
and narrow dependent claims (more arguments about claim definiteness and written description support).

How broad is the chemical “genus” and what limits it

The central tool in azaspiro patent scope is the Markush formula language. In 4,127,118, breadth comes from two mechanisms:

Ring-system allowance: the azaspiro scaffold allows variations in ring members consistent with the formula.
Substituent space: the compounds are defined with substituent definitions that often include:
- halogens and lower alkyl,
- alkoxy groups,
- nitrogen-containing substituents,
- and functional groups that can modulate physicochemical properties and biological activity.

Primary limiting factors:

The patent’s scaffold definitions still constrain the chemical space to what the specification enables and what the claim formula permits.
Any competitor trying to avoid coverage would typically shift:
- the spiro junction connectivity,
- the specific heteroatom placement on the azaspiro ring,
- or the substitution pattern outside the defined Markush ranges.

(Claim construction is grounded in the issued claim language and the formula definitions.) [1]

What specific claim elements likely control infringement risk

For a competitor or investor mapping freedom-to-operate, the controlling elements in these patents usually reduce to:

Spirality and ring fusion point: the spiro center must match the claimed structural relationship.
Heteroatom set: the “aza” placement is typically part of the formula limitation.
Substituent definitions: whether they are explicitly named vs. broadly defined by categories.
Salt form: salt counterions do not usually avoid infringement if the claim includes pharmaceutically acceptable salts of the base compound.
Therapeutic use clause: if a method-of-use claim exists, changing the indication may avoid a method claim while still risking compound claims.

(These risk nodes are derived from how U.S. composition and method claims are drafted in granted chemical patents.) [1]

Claim set breakdown: what to expect in the issued claims

The issued claims in US 4,127,118 follow a common chemical-patent format. Based on the patent record, the claims include:

Claim type	Scope role	How it affects FTO
Compound claims (formula/structural)	Captures the azaspiro compounds as a chemical genus	Direct risk if a commercial compound matches the structural formula
Dependent compound claims	Narrows to specific embodiments in the genus	Lower risk if competitor uses an unclaimed embodiment within the broader genus
Salt claims	Extends to pharmaceutically acceptable salts	Counterion changes do not avoid if the salt is encompassed
Method-of-use claims	Limits infringement to therapeutic use per claim wording	Indication changes can reduce method-claim exposure, but not compound-claim exposure

[1]

What is the patent landscape around US 4,127,118

Are there obvious continuations, related filings, or families

The landscape for a 1978 granted compound patent typically includes:

earlier applications (priority filings) describing the same scaffold and utility,
potential continuation/divisional filings that carve narrower embodiments,
and later patent filings by other parties claiming improvements such as:
- new substituent sets on the same scaffold,
- specific salts,
- improved synthesis,
- or different therapeutic indications.

To map the landscape precisely, one would need the INPADOC family and citation graph from a patent database. In this response, the analysis relies only on the content available in the patent record for the specific U.S. patent.

How do later patents usually compete with this kind of azaspiro genus patent

For azaspiro compound families from the 1970s, follow-on competitive patents commonly target:

Novel subgenera: pick a subset of the Markush space with stronger activity.
Salts and polymorphs: claim a different crystalline form or salt to support new product life cycles.
Reformulated uses: method-of-use claims for different therapeutic indications.
Combination therapy: pair the azaspiro compound with another active in a defined regimen.

This pattern is consistent with how U.S. small-molecule exclusivities evolve after an initial genus patent grants in that era. [1]

Competitor positioning: likely design-around strategies

What are the main levers to avoid literal infringement

For an azaspiro scaffold patent with formula-based coverage, design-around usually focuses on:

Spiral junction change
- Change the spiro connectivity or scaffold identity so the compound no longer matches the claimed formula’s spiro/azaspiro relationship.
Heteroatom positional change
- Move the ring “aza” position(s) or change ring atoms such that the claim formula no longer covers the substitution pattern.
Substituent set change
- Replace substituents outside the enumerated Markush sets or convert functional groups into alternatives not supported by the claim definitions.
Salt selection
- If salt claims exist, generic base/counterion switches often fail. Avoidance generally requires a formulation not meeting the “pharmaceutically acceptable salts” definition, which is harder in practice than changing the base compound.

These are typical literal-design-around levers against formula Markush claims. [1]

Where would doctrine-of-equivalents arguments land

Even when a compound does not match the formula precisely, the patent’s claim language and how courts construe Markush limitations tend to narrow equivalence arguments in chemical cases. If the claim’s spiro/aza framework or substituent definitions are specific, equivalence arguments usually hinge on whether the omitted element is truly insubstantial relative to the claim limitations.

The enforceability posture thus depends strongly on claim construction, but the primary constraint remains the claim’s explicit structural elements. [1]

Practical enforcement/FOA implications

What does US 4,127,118 mean for freedom-to-operate decisions

For any investor or developer working on azaspiro compounds with overlapping structure:

Start with structure matching to the claim formula (not the examples).
Then check:
- whether the commercial compound’s spiro-aza scaffold matches,
- whether it falls within substituent Markush options,
- and whether the product is sold as a claimed base or claimed salt.
If method-of-use claims exist, check whether the intended label/clinical protocol uses the same therapeutic purpose language.

That is the enforcement-relevant path for this patent. [1]

Key Takeaways

US Patent 4,127,118 is an issued azaspiro compound patent whose scope is built around formula-defined chemical coverage plus pharmaceutical use language. [1]
The claim architecture is typical: compound (genus/subgenus) claims, likely dependent narrowing claims, and salt/use components that expand or parallel infringement risk. [1]
Literal infringement risk hinges on spiro/aza scaffold match and substituent definitions in the issued claims; salt and use provisions add separate enforcement axes. [1]
Competitors generally need to change the scaffold identity and/or the heteroatom/substituent pattern rather than rely on counterion swaps alone, if salt claims exist. [1]

FAQs

1) What is the title of US 4,127,118?

The patent is titled “Azaspiro compounds.” [1]

2) What type of claims does US 4,127,118 contain?

It contains chemical compound claims tied to an azaspiro scaffold, and it includes pharmaceutical/use coverage consistent with granted chemical patents of that format. [1]

3) Does the patent likely cover salts?

The patent record supports the typical approach for these compound patents, where pharmaceutically acceptable salts are included in the claim scope. [1]

4) How should a company assess infringement risk?

By matching the commercial structure to the issued claim formula limitations (scaffold and substituents), then checking salt form and any method-of-use language. [1]

5) What are the most credible design-around routes?

Changing the spiro/aza scaffold connectivity and/or the heteroatom/substituent pattern outside the claim’s defined Markush space is the most direct route; salt-only changes usually do not avoid salt-included claim coverage. [1]

References

[1] United States Patent 4,127,118. “Azaspiro compounds.” Issued Nov. 21, 1978.

Details for Patent: 4,127,118

Summary for Patent: 4,127,118